PATH vs TMCI · P/E 19, rev $1.61B vs rev $209.4M
Uipath Inc (PATH) versus Treace Medical Concepts Inc (TMCI) — a side-by-side from cached financials, not a winner call.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Treace Medical Concepts Inc (TMCI) is a medical devices company listed on NASDAQ.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Latest reported TMCI revenue for 2024-12-31 was $209.4M. Net income was -$55.7M. Revenue was up 11.9% from 2023-12-31 to 2024-12-31. TMCI currently screens at market cap $260.1M.
PATH currently screens at market cap $6.07B and trailing P/E 19.4. TMCI currently screens at market cap $260.1M.
Not investment advice. Open the PATH and TMCI stock pages for the full models.
Not investment advice.